BeiGene: FDA to Review Brukinsa Combo in Relapsed, Refractory Follicular Lymphoma
By Colin Kellaher BeiGene on Wednesday said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of Brukinsa for...
Stay updated with breaking news from Beigene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Colin Kellaher BeiGene on Wednesday said the U.S. Food and Drug Administration has accepted its application seeking expanded approval of Brukinsa for...
BeiGene, Ltd. (NASDAQ:BGNE – Free Report) CFO Julia Aijun Wang sold 472 shares of BeiGene stock in a transaction dated Monday, July 3rd. The stock was sold at an average price of $179.55, for a total value of $84,747.60. The transaction was disclosed in a document filed with the SEC, which is available at this […]
BeiGene, Ltd. (NASDAQ:BGNE – Free Report) CFO Julia Aijun Wang sold 472 shares of the firm’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $179.55, for a total transaction of $84,747.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through […]
BeiGene, Ltd. (NASDAQ:BGNE – Free Report) CFO Julia Aijun Wang sold 472 shares of the business’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $179.55, for a total transaction of $84,747.60. The sale was disclosed in a legal filing with the SEC, which is available through […]
BeiGene, Ltd. (NASDAQ:BGNE – Free Report) insider Lai Wang sold 1,108 shares of the stock in a transaction dated Monday, June 26th. The stock was sold at an average price of $181.92, for a total value of $201,567.36. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. […]